Furthermore, we revealed a mechanism by which SOX9 regulates the expression and nuclear translocation of MMS22L and oxaliplatin resistance in CRC cells and provided a new focus for solving the problem of oxaliplatin resistance in CRC patients. Here, MMS22L is linked to colorectal carcinoma.